Compare Signpost Corp. (Tokyo) with Similar Stocks
Dashboard
1
Poor Management Efficiency with a low ROE of 5.07%
- The company has been able to generate a Return on Equity (avg) of 5.07% signifying low profitability per unit of shareholders funds
2
Flat results in Feb 26
3
With ROE of 5.18%, it has a very expensive valuation with a 1.68 Price to Book Value
4
Below par performance in long term as well as near term
Stock DNA
Pharmaceuticals & Biotechnology
JPY 2,303 Million (Micro Cap)
32.00
NA
0.00%
-0.70
4.07%
1.23
Revenue and Profits:
Net Sales:
888 Million
(Quarterly Results - Feb 2026)
Net Profit:
78 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-57.78%
0%
-57.78%
6 Months
-61.83%
0%
-61.83%
1 Year
-74.25%
0%
-74.25%
2 Years
-66.0%
0%
-66.0%
3 Years
-80.63%
0%
-80.63%
4 Years
-80.5%
0%
-80.5%
5 Years
-91.09%
0%
-91.09%
Signpost Corp. (Tokyo) for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
7.82%
EBIT Growth (5y)
15.60%
EBIT to Interest (avg)
-64.17
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-0.76
Sales to Capital Employed (avg)
1.39
Tax Ratio
Tax Ratio is Negative%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
14.37%
ROE (avg)
5.07%
Valuation key factors
Factor
Value
P/E Ratio
32
Industry P/E
Price to Book Value
1.68
EV to EBIT
42.72
EV to EBITDA
42.23
EV to Capital Employed
3.67
EV to Sales
0.56
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
8.60%
ROE (Latest)
5.18%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bearish
Bearish
RSI
No Signal
No Signal
Bollinger Bands
Bearish
Bearish
Moving Averages
Bearish (Daily)
KST
Bearish
Bearish
Dow Theory
Mildly Bullish
Mildly Bearish
OBV
No Trend
Mildly Bearish
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Quarterly Results Snapshot (Consolidated) - Feb'26 - QoQ
Feb'26
Nov'25
Change(%)
Net Sales
888.10
797.10
11.42%
Operating Profit (PBDIT) excl Other Income
92.00
27.30
237.00%
Interest
1.70
1.30
30.77%
Exceptional Items
0.00
-0.40
100.00%
Consolidate Net Profit
78.00
25.00
212.00%
Operating Profit Margin (Excl OI)
103.40%
34.00%
6.94%
USD in Million.
Net Sales
QoQ Growth in quarter ended Feb 2026 is 11.42% vs 6.14% in Nov 2025
Consolidated Net Profit
QoQ Growth in quarter ended Feb 2026 is 212.00% vs 1,236.36% in Nov 2025
Annual Results Snapshot (Consolidated) - Feb'26
Feb'26
Feb'25
Change(%)
Net Sales
3,138.90
3,023.50
3.82%
Operating Profit (PBDIT) excl Other Income
98.90
200.20
-50.60%
Interest
9.00
2.70
233.33%
Exceptional Items
-0.40
-1.30
69.23%
Consolidate Net Profit
76.20
257.20
-70.37%
Operating Profit Margin (Excl OI)
31.40%
66.20%
-3.48%
USD in Million.
Net Sales
YoY Growth in year ended Feb 2026 is 3.82% vs 3.20% in Feb 2025
Consolidated Net Profit
YoY Growth in year ended Feb 2026 is -70.37% vs 99.69% in Feb 2025
About Signpost Corp. (Tokyo) 
Signpost Corp. (Tokyo)
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates 
No Company Details Available






